Previous 10 | Next 10 |
Accolade has seen solid growth throughout the second half of 2020, now accompanied by some margin improvements as well. I like what I'm seeing as the company made a savvy deal as well at the start of this year. Shares look rather interesting to me here, certainly on a relative bas...
Accolade (ACCD) has priced $250M of 0.50% convertible senior unsecured notes due April 1, 2026 in a private placement.Initial purchasers granted an option to purchase up to an additional $37.5M of the Notes.Offering is expected to close on March 29. Interest will be payable semiannually ...
SEATTLE, March 25, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) (“Accolade”) announced the pricing of $250 million aggregate principal amount of 0.50% convertible senior notes due 2026 (the “Notes”) in a private placement (the “offering”) ...
Accolade (ACCD) announces private offering of $250M principal amount of convertible senior notes due 2026.Initial purchasers' overallotment option is additional $37.5M of notes.The company intends to use a portion of the net proceeds to pay the cost of the capped call transactions a...
SEATTLE, March 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) today provided preliminary unaudited financial results for the fiscal fourth quarter and year ended February 28, 2021 (fiscal year 2021). Based on current information, the company expects to report revenue for the fis...
SEATTLE, March 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) (“Accolade”) announced today that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2026 (the “Notes”) in ...
SEATTLE, March 04, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced it has completed the acquisition ...
SEATTLE, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the following upcoming i...
New Independent Study Finds Accolade Significantly Bends the Healthcare Cost Curve for Employer Aon study shows that Accolade lowered employer claims costs across major clinical categories and risk groups PR Newswire SEATTLE , Feb. 4, 2021 /PRNewswire/ -- Hea...
Accolade Welcomes Cindy R. Kent to its Board of Directors Business leader, healthcare executive and one of Savoy Magazine's 2020 leading executives is driving positive change for the healthcare experience in the U.S. PR Newswire SEATTLE , Jan. 27, 2021 /PRNew...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...